<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>mesothelioma</title>
    <link>/mesothelioma/drugpanel/bleomycin/</link>
      <atom:link href="/mesothelioma/drugpanel/bleomycin/index.xml" rel="self" type="application/rss+xml" />
    <description>mesothelioma</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Sun, 09 Sep 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png</url>
      <title>mesothelioma</title>
      <link>/mesothelioma/drugpanel/bleomycin/</link>
    </image>
    
    <item>
      <title>BLEOMYCIN</title>
      <link>/mesothelioma/drugpanel/bleomycin/info/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/drugpanel/bleomycin/info/</guid>
      <description>
&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;hr /&gt;
&lt;p align=&#34;left&#34; style=&#34;font-size:16px&#34;&gt;
DrugBank ID: &lt;a href=&#39;https://www.drugbank.ca/drugs/db00290&#39; target=&#39;_blank&#39;&gt;db00290&lt;/a&gt; &lt;br&gt;
DrugCentral: &lt;a href=&#34;http://drugcentral.org/?q=bleomycin&#34; target=&#34;_blank&#34;&gt;bleomycin&lt;/a&gt; &lt;br&gt;
Synonymous :bleocin | bleomicin | bleomicina | bleomycin | bleomycine | bleomycinum
&lt;/p&gt;
&lt;p&gt;&lt;br&gt;&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;drug-sentece-context&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;Drug Sentece Context&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 1.&lt;/strong&gt; Analysis of context sentence of &lt;em&gt;bleomycin&lt;/em&gt; gene in 7 abstracts.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
pmid
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
sentence
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15754636&#34; target=&#34;_blank&#34;&gt;15754636&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Intravenous injections of cisplatin and intrapleural application of bleomycin did not influence, however, the course of the disease.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20185425&#34; target=&#34;_blank&#34;&gt;20185425&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have previously reported that angiopoietin (Ang)-1 was correlated with bleomycin-induced pulmonary fibrosis.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21831962&#34; target=&#34;_blank&#34;&gt;21831962&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, unlike a G(2) checkpoint inhibitor, CBP501 clearly enhances the accumulation of tumor cells at G(2)-M phase that is induced by cisplatin or bleomycin at low doses and short exposure. […] We conclude that CaM inhibition contributes to CBP501’s activity in sensitizing cancer cells to cisplatin or bleomycin.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6202538&#34; target=&#34;_blank&#34;&gt;6202538&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the management of recurrent pleural effusions, intrapleural bleomycin, preceded by aspiration and followed by suction, was a useful alternative to surgery.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7542832&#34; target=&#34;_blank&#34;&gt;7542832&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical manifestation was a serosal effusion, which required weekly ascites puncture until therapy with intraperitoneal bleomycin was initiated. […] Unfortunately, intraperitoneal bleomycin was accompanied by pulmonary toxicity, but at a higher total dose than known for intravenous administration. […] Three years after diagnosis the patient is still alive, without relapse of ascites production after bleomycin had to be stopped. […] Considering the risk of pulmonary fibrosis with high-dose intraperitoneal bleomycin and the lack of efficacy on tumor reduction, bleomycin seems to offer no advantage with respect to cisplatin.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8622005&#34; target=&#34;_blank&#34;&gt;8622005&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the combination of doxorubicin, cisplatin, bleomycin, and mitomycin demonstrated a response rate of 44% (95% confidence interval, 27% to 63%), but this remains unconfirmed.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9363074&#34; target=&#34;_blank&#34;&gt;9363074&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Bleomycin also has its supporters, and a dark horse is quinacrine, which although not easily available in the United States, has been used in many European centers for decades.
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;
</description>
    </item>
    
  </channel>
</rss>
